In Vitro Diagnostics (IVD) in for rough ride in US
This article was originally published in Clinica
Executive Summary
US IVD manufacturers can expect a tough market in the short term, delegates at a HIMA meeting on November 8th and 9th were warned. The consensus of speakers at the meeting on regulatory and reimbursement issues affecting the in vitro diagnostic industry was that the market will become even more competitive as payers try to lower healthcare costs.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.